Core Insights - PharmAla Biotech Holdings Inc. has established a wholly-owned subsidiary, PharmAla Biotech Australia Pty Ltd., to conduct research and development activities in Australia [1][2] - The Australian market is recognized for its strong biotech development environment, which the company aims to leverage through existing relationships and expertise [2] - PharmAla Australia will hold a full and perpetual license to the ALA-002 asset and associated patents, enabling it to engage in manufacturing development and clinical research [2][3] Company Developments - The company appointed Dr. Evan Lewis to its Scientific Advisory Board, effective September 1, 2025, enhancing its expertise in clinical research and drug discovery [3][4] - Dr. Lewis has a background in neurology, particularly in epilepsy and pediatric neurology, and has previously led initiatives in psychedelic neurology and medical cannabis [4][5] - PharmAla is focused on alleviating the backlog of clinical-grade MDMA and developing novel drugs within the MDXX class, positioning itself as a leader in the psychedelics industry [6] Industry Context - Australia is highlighted as having a favorable regulatory environment for launching clinical trials, which is expected to benefit PharmAla's operations [3] - The company aims to capitalize on the growing ecosystem of biotech financiers and government incentives in Australia [3] - PharmAla is currently the only company providing clinical-grade MDMA for patient treatments outside of clinical trials, indicating a unique market position [6]

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”). “We believe that this delivery set ...

Core Insights - PharmAla Biotech Holdings Inc. has reported significant operational progress, including a large shipment of LaNeo MDMA to a U.S. distribution partner for clinical trials, and the completion of a manufacturing run for LaNeo Capsules in Australia [2][4] Financial Highlights - Customer deposits increased by $150,463 through Q3, with recognized revenue of $79,558, indicating a strong demand for clinical trial products [6] - Total expenses for the nine months ended May 31, 2025, were $2,117,495, compared to $1,085,458 for the same period in 2024, reflecting increased operational costs due to new hires and the cessation of capitalizing R&D costs [6] Company Overview - PharmAla focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the backlog of clinical-grade MDMA for trials and commercial sales [5] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials, emphasizing its regulatory relationships as a key to success in the psychedelics industry [5]

Core Insights - PharmAla Biotech Holdings Inc. has successfully completed an international shipment of LaNeo™ MDMA to Yale University for a clinical trial focused on Borderline Personality Disorder [1][2] - This shipment follows a previous successful delivery to the University of Washington, indicating PharmAla's growing role in clinical research involving MDMA [2] - The company aims to expand its market presence through these clinical trials, which could lead to new therapeutic applications for its products [2] Company Developments - PharmAla has granted MAPS authorization to publicly post its Investigator's Brochure, enhancing access to research on MDMA for global researchers [3][4] - The company has issued options totaling 1,500,000 shares to various board members and officers, with a fixed exercise price of $0.105, vesting over a 12-month period [5][6][7] - PharmAla's CEO, Nicholas Kadysh, will participate in the Canadian Security Exchange's Summit on Responsible Investment, highlighting the company's commitment to responsible practices in the biotech sector [8] Company Overview - PharmAla Biotech focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company providing clinical-grade MDMA for patient treatments outside of clinical trials [9] - The company aims to alleviate the backlog of generic, clinical-grade MDMA and develop novel drugs, positioning itself as a regulatory-first organization in the psychedelics industry [9]

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect c ...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and subsequent development. “Over the past year, our ...

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2025. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statements for th ...